Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆
Sander Lefere, Tobias Puengel, Jana Hundertmark et al. · Journal of Hepatology · 2020
Cited by 307 works. doi:10.1016/j.jhep.2020.04.025
Authors
- Sander Lefere
- Tobias Puengel
- Jana Hundertmark
- Christian Penners
- Anna Katharina Frank
- Adrien Guillot
- Kevin De Muynck
- Felix Heymann
- Vanessa Adarbes
- Evelyne Defrêne
- Céline Estivalet
- Anja M. Geerts
- Lindsey Devisscher
- Guillaume Wettstein
- Frank Tacke
References
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- PPARγ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
- Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
- Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
- Adipocyte-Derived Th2 Cytokines and Myeloid PPARδ Regulate Macrophage Polarization and Insulin Sensitivity
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening